Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma By Evelyn Warner 1 minutemin June 20, 2017 -Updated: onJune 23, 2022 1 minutemin Share WhatsApp Twitter Linkedin Email Newsletter Signup - Under Article / In Page"*" indicates required fieldsCommentsThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly.Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to its preclinical candidate, ARGX-112, though an amount has not been disclosed.The antibody, indicated for inflammatory skin diseases, was discovered with the biotech’s SIMPLE discovery platform. The Belgian biotech will carry out preclinical R&D on ARGX-112; once it hits the clinic, Leo will take over. Under the terms of the deal, the pharma holds the option to exclusive global licensing.Image via Copula / shutterstock.comArtificial intelligence and the future of antibody discovery Discover how AI and ML are already shaping therapeutic antibody discovery and explore their future potential. Read full report Explore other topics: AntibodiesArgenxBelgiumDenmarkLeo Pharma ADVERTISEMENT